Windtree Therapeutics Inc (WINT)

[H2R]

WINT Cash Position

As of December 31, 2016, the Company had cash and cash equivalents of $5.6 million.

In February 2017, the Company completed a private placement offering of 7,049 Series A Convertible Preferred Stock units for net proceeds of approximately $10.5 million, including $1.6 million of non-cash consideration in the form of a reduction in amounts due for current development services that otherwise would have become payable in cash in the first and second quarters of 2017.

The Company anticipates that, before any additional financings, its currently existing cash resources are sufficient to fund its operations through the planned completion of the AEROSURF phase 2b clinical trial and announcement of results in mid-year 2017.

I hope they get the PPS up before the next round of funding, hopefully with the top line data. I may add to my position after the next offering and/or the top line data, if positive.